primary ciliary dyskinesia

ReCode Therapeutics

Dallas Biopharma ReCode Therapeutics Gets $80M Series A Investment for Lung Disease Drugs

by | Mar 27, 2020
The investment from multiple sources, including local early-stage investor Hunt Technology Ventures, is the largest funding round by a startup this year in Dallas-Fort Worth.
MORE